- NCIt
- C3992
Loading cancer entity…
Loading cancer entity…
Clinical trials
18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05510973 | Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi | completed | N/A | 700 | Elizabeth Glaser Pediatric AIDS FoundationOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05510908 | Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC | completed | — | 460 | AIDS Malignancy ConsortiumNETWORK | 2 | Aug 14, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT03596918 | Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine | completed | — | 10 | AIDS Malignancy ConsortiumNETWORK | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05411237 | Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma | not yet recruiting | Phase 3 | 130 | AIDS Malignancy ConsortiumNETWORK | 0 | Jan 23, 2026 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | terminated | Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT01752569 | A Study of Selumetinib in Patients With Kaposi's Sarcoma(SCART) | terminated | Phase 1 / Phase 2 | 19 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00020683 | A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01016730 | Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2018 | clinicaltrials |
| NCT02137564 | Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Jul 23, 2015 | clinicaltrials |
| NCT00834457 | A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe | completed | Phase 2 / Phase 3 | 49 | Parirenyatwa HospitalOTHER | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00521092 | Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 5, 2014 | clinicaltrials |
| NCT00064142 | Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00003350 | Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma | completed | Phase 3 | 240 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00587912 | AIDS and Cancer Specimen Bank (ACSB) | completed | — | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 21, 2011 | clinicaltrials |
Data updated 19 days agoSource updated Sep 10, 2026source: clinicaltrials